

10/560282

AP13 Rec'd PGT/PTO 12 DEC 2005
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q91632

Takahiro KURAMOCHI, et al.

Appln. No.: Based on PCT/JP04/008479

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: December 05, 2005

Examiner: Unknown

For: BENZAMIDE DERIVATIVE OR SALT THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith on CD-ROM, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP04/008479
Attorney Docket No.: Q91632

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/008479 dated September 7, 2004), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

Also Applicant's have advised that the following documents correspond to each other:

| PCT publication | US corresponding Patent |
|-----------------|---|
| WO 2002/008221 | US 2002132853 |
| WO 2003/014064 | US 2004259875 |
| WO 2003/068749 | none |
| WO 2001/021577 | none |
| WO 2003/035624 | US 2005209213 |
| WO 98/41508 | US 2001016657 US 2003144320 US 2004209912 US 6841560 |
| WO 9748683 | US 6110934 |
| WO 2003/055848 | US 2005154230 |
| JP2003/55209 | none |
| JP2002/3370 | none |
| WO 2004/072069 | none |
| WO 2004/056774 | none |
| WO 2004/108133 | US 2005004133 |

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

10/560282

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP04/008479
Attorney Docket No.: Q91632

AP13 Rec'd PCT/PTO 12 DEC 2005

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Mark Boland
Registration No. 32,197

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: December 12, 2005

| | | | | | |
|--|---|----|------------------------|--------------------------|--|
| Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | Based on PCT/JP04/008472 | |
| | | | Confirmation Number | Unknown | |
| | | | Filing Date | December 05, 2005 | |
| | | | First Named Inventor | Takahiro KURAMOCHI | |
| | | | Art Unit | Unknown | |
| | | | Examiner Name | Unknown | |
| | | | Attorney Docket Number | Q91632 | |
| Sheet | 1 | of | 1 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|-----------------|--------------------------------------|--------------------------------|---|
| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
| | | Number | Kind Code ² (if known) | | |
| | | US 2002132853 | | | |
| | | US 2004259875 | | | |
| | | US 2005209213 | | | |
| | | US 2001016657 | | | |
| | | US 2003144320 | | | |
| | | US 2004209912 | | | |
| | | US 6841560 | | | |
| | | US 6110934 | | | |
| | | US 2005154230 | | | |
| | | US 2005004133 | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|---|-----------------------------|---|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Translation ⁶ |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ <i>(if known)</i> | | | |
| | | WO | 03/55848 | A2 | 07-10-2003 | BAYER AKTIENGESELLSCHAFT | |
| | | WO | 03/68749 | A1 | 08-21-2003 | GLAXO GROUP LIMITED | |
| | | WO | 02/8221 | A2 | 01-31-2002 | NEUROGEN CORP | |
| | | JP | 2003-55209 | A | 02-26-2003 | Bayer AG | |
| | | JP | 2002-3370 | A | 01-09-2002 | Takeda Chemical Industries, Ltd. | |
| | | WO | 03/014064 | A1 | 02-20-2003 | BAYER AKTIENGESELLSCHAFT | |
| | | WO | 03/035624 | A1 | 05-01-2003 | TAKDEA CHEMICAL INDUSTRIES | Abstract |
| | | WO | 98/41508 | A1 | 09-24-1998 | SMITHKLINE BEECHAM PLC | |
| | | WO | 97/48683 | A1 | 12-24-1997 | SMITHKLINE BEECHAM PLC | |
| | | WO | 2004/108133 | A2 | 12-16-2004 | VERTEX PHARMACEUTICALS INCORPORATED | |
| | | WO | 01/021577 | A2 | 03-29-2001 | TAKEDA CHEMICAL INDUSTRIES | |
| | | WO | 04/072069 | A1 | 08-26-2004 | GLAXO GROUP LIMITED | |
| | | WO | 04/056774 | A2 | 07-08-2004 | NEUROGEN CORPORATION | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|--------------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published. | Translation ⁶ |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.